X

Trial Profile

Evaluation of PegIntron in control of hepatitis C Cirrhosis 3

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Feb 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Acronyms EPIC-3
Sponsors Schering-Plough

Most Recent Events

18 Apr 2010 Results from EPIC3 were presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
30 Oct 2009 Results from EPIC-3 Maintenance Trial presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
26 Apr 2009 Results from EPIC-3 Maintenance Trial presented at EASL 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com